![](https://endpts.com/wp-content/uploads/2020/10/News_briefing_FE.jpg)
Verve names second PCSK9 candidate; Exscientia picks another AI-created molecule for clinic
Boston-based Verve Therapeutics has unveiled its second PCSK9-targeting program.
The biotech announced the candidate, dubbed Verve-102, as part of its wider third-quarter financial results. Verve …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.